

Programme of work April 2007-March 2012

Version 4: 25 January 2007

2	A) SUMMARY	
3	B) THE RESEARCH PROPOSAL	
3	B) 1. BACKGROUND	
4	b) 1.1. Theme 1: The national smoking cessation picture	
7	b) 1.2. Theme 2: The national smoking cessation picture: a review of the current evidence on smoking cessation	
8	b) 1.3. Theme 3: Developing and testing a new smoking cessation programme	
10	B) 2. STUDIES	
10	b) 2.1. Study group 1: The Smoking Cessation Clinic (SCC)	
12	b) 2.2. Study group 2: Analyzing data from existing smoking cessation programmes	
15	b) 2.3. Study group 3: The Stop Smoking Clinic Research Network (AM, ML, JL, EV, DS, RW)	
18	b) 2.4. Study group 4: The Stop Smoking Clinic Research Network (AM, ML, JL, EV, DS, RW)	
18	b) 2.5. Study group 5: Evaluation of Tabex (cytisine) as an aid to cessation (RW, JS)	
22	b) 2.6. Study group 6: The Stop Smoking Clinic Research Network (AM, ML, JL, EV, DS, RW)	
22	b) 2.7. Study group 7: A new smoking cessation programme	
23	b) 2.8. Study group 8: A new smoking cessation programme	
25	b) 2.9. Study group 9: A new smoking cessation programme	
	B) 3. OVERVIEW	
	B) 4. COMMUNICATION AND	

a) Summary

The aim of the programme is to produce findings that increase the rate at which smokers are motivated to try to stop and succeed in doing so, with the ultimate goal of reducing the harm caused by tobacco use. There are three themes to the proposed programme which are linked to seven groups of studies. The themes are: 1) collecting timely and accurate information on the national smoking cessation picture, 2) improving understanding of the process of smoking cessation, and 3) developing and evaluating interventions to promote and aid cessation.

The seven groups of studies are:

1) *Smoking Toolkit Study (STS)* - A rolling programme of household surveys and associated follow-ups to provide vital national statistics on rates of attempts to stop smoking, use of aids in those attempts, 6-month continuous abstinence rates following those attempts, triggers of those attempts, and reasons for relapse following attempts.

2) *Analysis of existing and ongoing data sets* - Examining a range of issues including effectiveness of nicotine replacement therapy, behavioural support, patterning of quit attempts, success rates of quit attempts, and short- and medium-term changes in physical health and quality of life in ex-smoking smokers.

3) *Development of a new nicotine replacement therapy (NRT) product* - A nasal spray without behavioural components as a function of past quit attempts, and mental health and healthcare costs.

4) *Evaluation of the nicotine gum* - The like-for-like comparison of obtaining nicotine through the gum versus other NRT products. A study comparing the effectiveness of this device including a pharmacokinetic study of this device versus other NRT products on ad lib use.

5) *Development of a new NRT product* - A study comparing the effectiveness of this device including a pharmacokinetic study of this device versus other NRT products on ad lib use.

6) *The process of change studies* - This is a series of studies involving an interview-based postal survey with follow-up and a series of experimental studies to test hypotheses about the process of change in smoking cessation.

7) *Activating conditional processes to motivate smoking cessation* - Funded by the Department of Health, this study involves specific techniques to motivate smokers to ultrasound images of their carotid arteries.

8) *Development of a new NRT product* - A study comparing the effectiveness of this device including a pharmacokinetic study of this device versus other NRT products on ad lib use.

9) *Development of a new NRT product* - A study comparing the effectiveness of this device including a pharmacokinetic study of this device versus other NRT products on ad lib use.

10) *Development of a new NRT product* - A study comparing the effectiveness of this device including a pharmacokinetic study of this device versus other NRT products on ad lib use.

In addition to the research studies, a major component of the programme is communication activities and policy development. This includes continued guidance and support to national and international agencies involved in tobacco cessation and undertaking major systematic reviews.

b) The research proposal

b) 1. Background

The overall aim of the programme is to produce research findings that will contribute to a reduction in tobacco-related harm through smoking cessation, first and foremost in the UK but also

in other countries. The programme will be funded for specific projects, which will be selected on the basis of the experience of the research team including members who

are currently funded for specific projects. The programme will be funded for specific projects, which will be selected on the basis of the experience of the research team including members who

are currently funded for specific projects. The programme will be funded for specific projects, which will be selected on the basis of the experience of the research team including members who


are currently funded for specific projects. The programme will be funded for specific projects, which will be selected on the basis of the experience of the research team including members who

Figure b) 1.1.1: A population model of smoking cessation (see text for explanation)


a) Model for all quit attempts



b) Model showing use of aids to quit attempts



c) Model showing triggers and aids to quit attempts



(iii) Success rate of quit attempts to quit smoking and the proportion of long...

The success rate of quit attempts to quit smoking is widely used as a measure of success of unaided quit attempts is about 4% lasting 10 months or more (10). This is based on a survey of 1000 smokers in the UK (21). Because quit attempts that fail are often very quickly forgotten, single surveys asking about quit attempts over 12 months to make estimates is not appropriate. Related to (ii) we currently have no adequate population level data on the proportion who were successful in quitting smoking. However, a recent study (22) shows that 22% of smokers seeking help made a quit attempt in the previous 12 months, 12% of those who made a quit attempt in the previous 12 months were successful in quitting smoking. This is a very low success rate and is likely to be inflated due to recall bias from prospective studies and wholly unrealistic.

c) Model showing triggers and aids to quit attempts

events that prompt quit attempts. Surveys ask about reasons for stopping smoking which is not the same thing (19). From a policy perspective it is important to be able to link quit attempts with

to determine whether and how far to by involves the having of triggers. The investigate triggers and the results suggest that studying triggers is feasible. It is able to link triggers with the use of different aids to quitting and ultimately success tant to know, for example, whether quit attempts promoted by GP advice are more use of NRT or NHS Stop Smoking Services and whether they are more or less eepful, other things being equal.

triggers or trigger SPP sought to also useful to be rates. It is impor likely to involve likely to be success

Social and personal factors influencing

res an understanding of the personal and social factors that t methods to stop and their likelihood of success in stopping.

Interpreting the above figures requi contribute to smokers using differen

Support for NRT and are tribution that use of these to collect such data (see

For example, if smokers that are more nicotine dependent use behaviours less likely to be able to stop, this may lead to underestimation of the com methods makes to success of quit attempts (24). It is therefore essential 25).

Control (ITC) cohort study t take account of multiple nt to overcome issues of tion the UK sample is too e. An international multinational cohort of smokers every 3 months for 2.5 years (27). The use of up goes a long way to addressing problems of recall bias but the UK sample is too king in the next 3 months.

Ongoing studies relevant to these issues: The International Tobacco C (26) includes assessment of quit attempts and success rates but does not quit attempts in a 12-month period and the follow-ups are too infrequent recall bias when it comes to accurately assessing success rates. In addition following to a quarterly follow-up cigarettes per day who at baseline said that they intended to stop smok

On this topic, most notably in

There are a number of studies overseas that seek to address (22, 28, 29). Lowly account of multiple quit attempt

conclusions regarding aids to
workers and gender

smoking (42-46). However, there are lessons that

resistance to anti-smoking campaigns (47) and failure of attempts to stop smoking

regarding self-help smoking cessation (48) and (49). The role of identity for example, there is a large literature but mostly on adolescent smoking

on which the theory is based is described in more detail (50). West (49) fits with the theory. Evidence of

age and the likely

have begun to be explored.

ports suggests that, other things being equal, these

change than those that are planned in advance

advantage of unplanned quits will become manifest to a

epiphany)

quit attempt,

new identity as a non-smoker would be expected to play a greater role:

as non

abstinence: 1.4MM

will be maintained once other potential confounding factors

planning: of wanting to stop smoking: participants: 1.1MM

states report intending to stop in the future) in predicting quitting (50). According to

ory this is because the responses to questions about future quitting do not reflect how much

they actually think about this when they smoke, or how much they think about when they

the state of mind in which they are smoking. PRIME Theory predicts that the frequency of feelings of

frustration of automated action schemas. PRIME Theory argues that individuals experience urges when they exercise voluntary restraint over impulses. Work the

current programme is a first attempt to test this hypothesis (see Section A)

would be expected given that it brings together existing mode brand evidence. A

role of identity for example, there is a large literature but mostly on adolescent smoking

identity and smoking cessation (42-46). However, there are lessons that

resistance to anti-smoking campaigns (47) and failure of attempts to stop smoking

regarding self-help smoking cessation (48) and (49). The role of identity for example, there is a large literature but mostly on adolescent smoking

on which the theory is based is described in more detail (50). West (49) fits with the theory. Evidence of

age and the likely

have begun to be explored.

ports suggests that, other things being equal, these

change than those that are planned in advance

advantage of unplanned quits will become manifest to a

epiphany)

quit attempt,

new identity as a non-smoker would be expected to play a greater role:

as non

abstinence: 1.4MM

will be maintained once other potential confounding factors

planning: of wanting to stop smoking: participants: 1.1MM

states report intending to stop in the future) in predicting quitting (50). According to

ory this is because the responses to questions about future quitting do not reflect how much

they actually think about this when they smoke, or how much they think about when they

the state of mind in which they are smoking. PRIME Theory predicts that the frequency of feelings of

frustration of automated action schemas. PRIME Theory argues that individuals experience urges when they exercise voluntary restraint over impulses. Work the

current programme is a first attempt to test this hypothesis (see Section A)

b) 1.3. Theme 3: Developing and testing better interventions

Developing improved methods to aid cessation: The top line conclusions regarding aids to smoking cessation are summed up in Box b) 1.3.1.

Box b) 1.3.1

1. Randomised controlled trials have found that individual counselling help with stopping improves ability to sustain abstinence for at least 6 months by an average of 4% when delivered face to face and a similar amount when delivered by telephone – this is compared with minimal support in the form of a brief motivational session or written materials alone (52, 53). There is insufficient information to determine whether one particular approach (e.g. motivational behavioural therapy) is better than another or what are the active ingredients. The evidence suggests that the effect of counselling is broadly additive to the effect of NRT. Evidence from

real-world application of behavioural support methods suggests that the benefits of behavioural support translate from the experimental trials into the routine clinical situation (54)

2. There is no evidence of harm. While medication trials have indicated no adverse effects from a range of support options, a recent study of a behavioural support package for people with a history of substance use (55)

showing help with stopping improves ability to remain abstinent for at least 6 months by an average 4% compared with placebo (56). It has also been strongly suggested that using

so that best practice can be established and disseminated. Key areas of enquiry are: use of specialist staff to treat smokers versus practice nurses or pharmacists, group versus one-to-one
appoint-based clinics.

b) 2. Studies

JF: Jenny Fidler, ML: Mark

Shahab, JS: John Stapleton, AB: Andrew Bryant, AM: Andy McE
Livermore, DR: David Boniface

IS, AM, IF, AB, DR)

primary aim of the study is to provide
relating to smoking cessation to guide
toolkit for understanding the process of
GP advice and aids to cessation such
as nicotine replacement therapy and behavioural support in the real world. Furthermore, it will
provide national data on smokers' attempts at harm reduction, specifically cutting down and the
use of aids to cutting down.

The unique feature of the study involves recognising that many smokers make multiple quit
attempts within a short space of time, and that unsuccessful quit attempts are often rapidly
forgotten. This means that surveys need to be carried out frequently and to concentrate on a more
needs to be able to cater for multiple
involve different triggers, use different

draw participants for other studies in

l samples of smokers
ple followed up after 3

depending on funding
by the social research

veys will use the BMRB omnibus

of regular series of surveys in which are not by questionnaire. Figure 12.1 in shows
assessments for the smallest feasible study involving quarterly baseline household
larger alternatives involve bimonthly baseline surveys or ideally monthly baseline

from each sample will agree to be followed up and complete the 3 month and 6 month postal
questionnaires. Half of these will be selected for provide address completed and return these by post.
minimum 24 samples for baseline and follow-up data for each of the 3 months and 6 months follow-up. This is

generated that the annual sample will
monthly cadence, participation of
500 and 1500 will provide complete

The role is on the law... be any person aged 16 or above who has agreed to take part in the
BMRB household survey. Appendix 2 shows the proposed baseline questionnaire. This has been
pilot tested as a postal questionnaire and in May 2006 we commissioned BMRB to test it again as
a household questionnaire in an omnibus survey exactly as it would be used in the full study. The
key assessments for each participant at each household survey will be: 1) the number of serious
quit attempts recalled as having been made within the last 3 months; 2) for each quit attempt made

used life would lower the system for people who

1. providing accurate up-to-date information on smoking prevalence including all smoked tobacco

with incidence of smoking; as well as cigarettes and including the 12-month, 3-month and 1-month

of tobacco cessation; 2. providing an annual update on the key cessation parameters

of cessation, including the proportion of smokers who quit, the proportion of smokers who quit with

and instructions of manual with a minimum 95% confidence intervals; 3. providing a

stratified by socio-economic groups, gender and age group proportions of smokers

working or otherwise; 4.

3. time series analyses to assess changes in each of the above parameters at whatever frequency they are assessed (quarterly, bimonthly or monthly) including seasonal trends,

and the impact of various factors such as price changes, advertising, etc.

medications, price changes etc.

regional regression analyses to assess the association between the use of specific

medications, price changes etc. and the proportion of smokers who quit.

5. random effects logistic regression analyses examining the association between use of specific

medications, price changes etc. and the proportion of smokers who quit.

6. random effects logistic regression analyses examining the association between use of specific

medications, price changes etc. and the proportion of smokers who quit.

7. random effects logistic regression analyses examining the association between use of specific

medications, price changes etc. and the proportion of smokers who quit.

8. construction annually of a full statistical

reporting the national smoking cessation picture.

9. random effects logistic regression analyses examining the association between use of specific

medications, price changes etc. and the proportion of smokers who quit.

10. linear regression comparing smokers reporting versus not reporting cutting down; with or

without NRT and saliva cotinine concentrations (logged)

11. logistic regression analyses to assess the association between cutting down, with or without

NRT, and subsequent quit attempts in the next 6 months adjusting for other predictors of quit

attempts; additional logistic regression analyses to assess the association between cutting

down, with or without NRT, and subsequent quit attempts in the next 6 months adjusting for other predictors of success.

12. correlations between quantitative measures of smoking and degree of addiction in continuing

smokers at baseline, 3 months and 6 months (cigarettes per day, saliva cotinine - 3 month and

6 month only, FTND)

methodology has been pilot tested and there is a high degree of confidence that it will produce

required data

findings from ongoing and

b) 2.2. Study group 2: Analysing data from and reporting

existing datasets

involves using existing data and ongoing data gathering exercises to answer key questions

that the national can answer. This research will continue through the final

cessation report

methodology

This data set (see earlier discussion) involved following a

sample of smokers drawn from five countries: UK, US, Canada, France and Spain. Data collection

completed in late 2005 but with a dataset of this complexity and potential value, it will require a

considerable research effort to address the range of key questions about smoking and smoking

cessation that the national can answer. This research will continue through the final

cessation report

methodology

This data set (see earlier discussion) involved following a

sample of smokers drawn from five countries: UK, US, Canada, France and Spain. Data collection

completed in late 2005 but with a dataset of this complexity and potential value, it will require a

considerable research effort to address the range of key questions about smoking and smoking

cessation that the national can answer. This research will continue through the final

cessation report

methodology

This data set (see earlier discussion) involved following a

sample of smokers drawn from five countries: UK, US, Canada, France and Spain. Data collection

completed in late 2005 but with a dataset of this complexity and potential value, it will require a

considerable research effort to address the range of key questions about smoking and smoking

cessation that the national can answer. This research will continue through the final

cessation report

period of the existing programme but will need to continue into the first year of the new programme

and possibly beyond. The proposed schedule of the first five papers arising from the cohort to be

produced under the new programme is: 1) The role of acute and chronic illness in prompting quit attempts and their relationship to success of those attempts; 2) The role of body weight and concern about increases in body weight as a barrier of attempts to stop smoking and to long-term success; 3) The short-term and medium-term benefits to physical and mental health of stopping smoking; 4) Methods used by smokers to help them stop as a function of different smoker

over a 2-year period. Modelling the temporal patterning of quit attempts and their success

in a general population. The modelled fit to the data from the study of 2009 smokers in the US, CA

made in France. Findings from the trial were of the study that included 2009 smokers in the US, CA

was added to France of whom 52% were followed up successfully for one year. Since then Spain

will be conducted in collaboration with R III. The proposed analyses are part of a planned sequence and will

estimates of statistical power cannot be. who were contracted to undertake the field work. Accurate

sample size would be sufficient to detect a power of greater than 80% in most ca

ses.

sample size would be sufficient to detect a power of greater than 80% in most ca

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

ses.

Clinic that has been completed by JS. Subjects were followed up for 12 months. The issue of

practice and theoretical importance. As noted earlier, data to date sug-
gest that combinations are
-data in which the combination has been compared with both individual forms.
addressed the issue. This trial was also designed to understand better the situation of
it might respond best to two forms of NRT at opposite ends of the pharmacokinetic
spectrum (patch with very slow release versus spray with rapid absorption). Direct com-
parison of only two, one involved members of this team (58) and the other
attempted to identify parameters that could help match smokers to treatments (72). This
build on those findings. Many smoking characteristics were measured, including
one sample before and immediately after smoking a cigarette, and a range of
tolerance and dependence scales. Thus the study offers the opportunity to examine
differences between smokers in terms of suitability for different forms of NRT.

Smoking Cessation Clinic Research Database (JS, JS, AM, RW)

since 1987, containing the full past treatment
and containing various group treatment comparisons of different forms of NRT. The database
is a structured database containing details for 100000 of
records as the progresses in cessation when not in the
to the study database and we will also be possible to examine the
this group, including level of nicotine dependence and
dependence, we found in the STP that smokers in the
in the FTND (see Appendix 1) but we could find no

recent years DNA samples have been collected
such database where full clinical and smoking
forms to withdrawal symptoms, long and short-

Aims and methodology

The Maudsley database has been maintained by JS
and contains details for 100000 of
records as the progresses in cessation when not in the
to the study database and we will also be possible to examine the
this group, including level of nicotine dependence and
dependence, we found in the STP that smokers in the
in the FTND (see Appendix 1) but we could find no
recent years DNA samples have been collected
such database where full clinical and smoking
forms to withdrawal symptoms, long and short-

b) 2.2.6. The ZORN trial (JS, EV, RW)

Aims and methodology

This is an RCT comparing the effectiveness of nicotine replacement therapy versus bupropion
versus a combination of the two as an aid to smoking cessation in the context of behavioural
support provided by NHS Stop Smoking Services (see section A b) 1.). Support has been provided

benefit of these treatments will be completed by the end of the current programme but
has been designed to answer further questions of fundamental importance in the
established mental health services. The trial is a randomised controlled trial comparing
treatments is an active area of study and some important findings are beginning
to emerge. For example, previous studies have shown that nicotine replacement therapy, per-
functionality, as indicated by pretreatment 3-HC/cotinine ratio derived

exciting finding that needs following up

programme). The network will also offer access to NHS Stop Smoking Service staff, whose knowledge and attitudes can be evaluated routinely and in response to specific interventions.

Finally, the network will be a major tool for building research capacity within the NHS Stop Smoking Services. The website (www.scsrn.org) provides valuable resources for services wanting to undertake their own audits of research projects and these need to be updated regularly. It also provides a simple system whereby services can upload reports of different headings so that other services can see what has been done.

Methodology

The website is currently being hosted for free by Exchange Supplies who are organising the UK National Smoking Cessation Conference and are happy to continue this relationship. However, the work involved in maintaining and developing the website and working with busy service managers to ensure that they make most effective use of it is more than can be

undertaken on present resources. This is a role that will be taken by other members of the research team, the programmer (MJ) and the PA and HBRC administrator with supervision by AM.

that members can report findings and share experiences and resources. Studies proposed for the network include:

1. Comparison of long-term success rates as a function of interventions
2. Comparison of 4-week success rates as a function of mode of delivery (drop-in clinic, pharmacy and group etc.)
3. Comparison of retention and outcome as a function of method of acquiring medication (one-stop GP, direct supply etc.)
4. Demand for, use of, and effectiveness of, different NRT combinations, as a function of NHS prescription or with one available
5. Methods used to increase referrals from GP and secondary care sources and their association with success rates.

For these studies will typically involve multiple random effects logistic regressions with dependent variables entered together with measured confounders (including free nicotine dependence and age) and with the stop smoking services as a random variable and where practice as another nested variable. These analyses will be complex and require

The analyses for these studies will be complex and require appropriate practical considerations.

depends on the quality of data collection by the stop smoking services. AM has already undertaken work with these services to bring data collection up to the required standard and continuing this liaison and training will represent a significant part of the programme.

Technical feasibility

The success of this series of studies depends on the quality of data collection by the stop smoking services. AM has already undertaken work with these services to bring data collection up to the required standard and continuing this liaison and training will represent a significant part of the programme.

b) 2.4. Study group 4: Evaluation of the Nicotine Cannon (AM, RW, JF, LS, EV, JS)

Aims and justification

We have been undertaking preliminary research with a novel nicotine delivery device that may help some smokers to stop more effectively than existing products. This is an area in which there is already a great deal of research and development (e.g. 88, 89). However, to date no single form of

device has been shown to be superior to existing products in terms of long-term abstinence in unselected smokers (58).

The use of delivery would represent an advance however, we believe that another

also be important – the ability of smokers to adjust on a moment to moment basis the delivery of nicotine and carbon attached to this. The Nicotine Cannon is a device that allows this to a greater degree than existing nicotine delivery systems. It involves five nicotine inhaler cartridges arranged in parallel in a wide bore tube (the diameter of a standard cigarette) around a central hollow core. The user inhales the nicotine vapour through a mouthpiece (the diameter of a standard cigarette) and the nicotine is delivered to the lungs through the central core. The user may need to hold the device in their mouth for a short time before inhaling.

The next steps are to examine the user may need and to determine whether the Cannon can deliver nicotine more rapidly and completely than existing nicotine products.

Methodology

Three studies are planned:

1. Pharmacokinetic study (Year 1). The method block will be the same as has been adopted for the pharmacokinetic study undertaken in the previous study.

2. Subjective effects study (Year 2). This will be a parallel study to the pharmacokinetic study (given that smokers will be the ultimate users of the product and there is evidence that smoking

also assess ratings of acceptability of the products, subjective effects and acute effects. The study will be conducted in a laboratory setting. The subjects will be instructed to take 10 puffs per minute. Blood will be taken at baseline, halfway through administration (5 minutes), and at 1, 5, 10, 15, 30 and 60 minutes after administration of nicotine has ceased. In addition the subjects will complete a 10-point rating scale on the presence of any of the following symptoms: nausea, throat irritation, dizziness, feeling unwell, pleasant feelings and agitation. These self-report ratings are made at the same intervals that blood is taken and are marked between 1 (none) and 10 (extreme). The subjects

This study will be conducted in a laboratory setting. The subjects will be instructed to take 10 puffs per minute. Blood will be taken at baseline, halfway through administration (5 minutes), and at 1, 5, 10, 15, 30 and 60 minutes after administration of nicotine has ceased. In addition the subjects will complete a 10-point rating scale on the presence of any of the following symptoms: nausea, throat irritation, dizziness, feeling unwell, pleasant feelings and agitation. These self-report ratings are made at the same intervals that blood is taken and are marked between 1 (none) and 10 (extreme). The subjects

variables. The secondary outcomes measures will be ratios of [redacted] period using baseline ratios as control. [redacted] acceptability of the products and usage of the products. [redacted]

Effect of the nicotine cannon on abstinence (Years 3 to 5)

b) 2.4.3 RCT of [redacted]

programme grant to support the involvement of the JDRG in this activity. This will involve staff working full-time, in leadership, coordination and stakeholder-related activities, developing an analysis and disseminating the findings.

An investigation into the potential for a programme of research that addresses the reasons that the manufacturers are not in a position to work with the systems on which the JDRG is based, and against profiteering, should the programme of research prove successful.

Methodology

follow-up using the Russell Standard outcome assessment. The course of as specified in the labeling for the drug in Poland where the trial will be carried out.

release of a relevant trial and study in the case of the drug, with the potential for a phase II and phase III study. The study will be a 12-month study comparing the existing smoking cessation medication as currently used and comparing vylisinc against existing smoking cessation medications. Further phase I and phase II studies are desirable but these can be conducted by other parties within the JDRG programme.

Technical feasibility

ensuring that the MRPI funded Tabex trial runs successfully. The feasibility of the remaining studies in the programme depends on external funding, but given the potential worldwide impact of this programme of research, there is considerable interest from a number of quarters and confidence is high that funding will be secured.

1.2.6 Study group 6: The Disease of Change studies (EV-15-16-AM-PMA)

urges to smoke that come unexpectedly or when there is a crisis or situation normally associated with smoking; 4) Evidence of chronic or acute distress that depletes mental resources necessary for the exercise of self control, and the expectation of escape from which may make a resumption of smoking attractive; 5) Evidence of continued feelings of attraction to smoking; 6) Evidence of

social and physical environment is populated by triggers, including other people smoking. This has been an area that has been most studied to date and the importance of situational factors is well established (see e.g. 36).

The theory also suggests themes relevant to the relapse process. These include: 1) How far smokers go from a conscious decision to smoke, emotion and thoughts not necessarily leading to a temporary exception to the rule of abstinence. Surprisingly we could find no studies that examined this issue. Preliminary analysis of this concept led to the co-investigator's

theory that conscious decisions to resume smoking are rare but current work on another study indicates that smokers do make such decisions. This is an area that has also received little attention. There has been extensive research on the 'abstinence violation effect' in which a lapse creates dissonance and feelings of

3) **Changes in identity** – smoked in a stress situation which released the stress (for example following lapses – the patterning of smoking behaviour following the lapse). The PRIME theory proposes a focus not only on rekindling of habit mechanisms and affect, on self-efficacy but also on escape from the stressor (e.g. 'I've given myself a break' 'I've benefited from a break' 'I've resumed smoker etc.).

The four projects currently under way that will feed into the studies for the new programme are:

1) (section 1b 36) – and a study being smoking urges (section 1b 36); the hypnotherapy pilot study on smokers and ex-smokers on various aspects of their motivation to smoke and not to smoke.

change would build on the findings from the work going on elsewhere on relapse (34-38, group the studies will be informed by the 96-99). Apart from the ongoing work of Shiffman's


Methodology

b) 2.6.1. Interviews with smokers and ex-smokers (Year 1)

The interviews will be undertaken in the homes of smokers and ex-smokers. The study will involve a total of 700 interviews with 100 smokers and 600 ex-smokers. The interviews will be conducted in the homes of participants or at the HRRQ. The interviews will be based on the PRIME theory. This attempts to determine for each individual the range of motivational forces contributing to their ongoing behaviour and what they are motivated by. The interviews will be conducted in the homes of participants or at the HRRQ. The interviews will be based on the PRIME theory. This attempts to determine for each individual the range of motivational forces contributing to their ongoing behaviour and what they are motivated by. The interviews will be conducted in the homes of participants or at the HRRQ. The interviews will be based on the PRIME theory. This attempts to determine for each individual the range of motivational forces contributing to their ongoing behaviour and what they are motivated by.

It will be noted that not all of the grid will be populated using different methods. Indeed, it is an open question how far the grid can be populated using different methods. It will be noted that not all of the grid will be populated using different methods. Indeed, it is an open question how far the grid can be populated using different methods.

Theory



questionnaire will be given to a sample of 500 smokers from the STS and use a fixed format version of the comprehensive motivational assessment grid to determine for each smoker their temporal profile of motivational tension regarding smoking. It will specifically compare the

Methodology

Because this study focuses on the cardiovascular system, we are s

protocol development and reporting relating to the study. This study aims to r
groups. In the treatment group, smokers attending a designated GP practice will be pro
conducted. Degree of ease of their cardiovascular estimation is not a time and cost

ity standards who will also deliver the intervention. During the scan, the results, which
on a screen, will be explained to participants and compared with that of a non-smoker.
participants will be provided with information regarding the link between arterial
d smoking, an accompanying leaflet and a picture print-out of their own arterial scan.
in the treatment group will also receive a standard cardiovascular risk assessment and
uraged to quit smoking. In the control group, participants will also receive a standard
his risk assessment but will not receive any biofeedback or leaflet. Smokers in

the control group will also be advised to quit. Participants would be followed up 6 month
intervention to ascertain biochemically validated smoking status, quit attempts and

sation behaviours.

Technical feasibility

Technical feasibility of this study depends on securing external funding and co-operation with

general practices involved. RML has also links with local general practices as this is not

method and a highly experienced ultrasonographer who works

with extensive experience of the

in undertake a more limited investigation with minimal supplier costs to explore in more detail the
lasting motivational effect of these kinds of images using the kind of motivational grid described
section b) 2.6.

b) 3. Overview

A summary of the key research questions is given in Box b) 3.

Box b) 3. Key research questions:

<p>and success of quit attempts? (Study 2.1)</p>	10. How
<p>Does experience of illness influence quitting behaviour? (Study 2.1, Study 2.7)</p>	11. What
<p>What are the short- and medium-term gains in physical and mental health associated with smoking cessation? (Study 2.1, Study 2.3)</p>	12. What
<p>What is the consistency of the experience of withdrawal symptoms over different quitting episodes? (Study 2.1, Study 2.5)</p>	13. Does the UK's national strategy for smoking cessation result in different quit rates compared to other countries? (Study 2.1)
<p>What is the impact of cessation services and reimbursement of smoking cessation on attitudes and behaviour among UK smokers compared to other countries? (Study 2.1, Study 2.8)</p>	14. How effective is nicotine nasal spray when used in a general practice setting with minimal support? (Study 2.2)
<p>Do short- and long-term relapse differ? (Study 2.3)</p>	15. To what extent do predictors of smoking cessation differ between different quit attempts? (Study 2.3)
<p>What is the impact of nicotine patch versus nasal spray versus the combination?</p>	16. What is the best measure of addiction? (Study 2.3)
<p>What is the impact of nicotine patch versus nasal spray versus the combination?</p>	17. Is there a difference in efficacy between different quit attempts? (Study 2.4)
<p>What is the impact of nicotine patch versus nasal spray versus the combination?</p>	18. Does peak plasma nicotine concentration predict relapse? (Study 2.4)
<p>What is the impact of nicotine patch versus nasal spray versus the combination?</p>	19. What is the impact of nicotine patch versus nasal spray versus the combination? (Study 2.4)
<p>What is the impact of nicotine patch versus nasal spray versus the combination?</p>	20. What is the impact of nicotine patch versus nasal spray versus the combination? (Study 2.5)



6. Continue as Assistant Editor, Addiction

John Stapleton:

1. Contributing to NICE guidance

Peer review
papers

2. Contributing to guideline sys
3. Contributing to ASH working

4. Expert statistical advice for Addiction

5. Advice on development of research

b) 5. Building capacity

Smoking Cessation Services Research Network (SCSRN): The SCSRN will conduct and

clinical good practice. The network will also nurture and support NHS Stop Smoking promote
in collecting reliable data for research purposes. Services

Research UK (TRUK): The team will also continue work that has been started on TRUK Tobacco
network of tobacco researchers in the UK and an associated website that aims to provide This is a

of these and resources. While progress has been made in the period of the staff increase ways of funding
of these resources prevented. It is not clear how to develop further programme built on this

ers: This programme aims to create the next generation of world-class Post-doctoral research

in addition, these researchers will be able to contribute to the generation of research on the most general
ected these. LS and EV represent the following generation. We are fortunate in having attracted
researchers to the field and the next task is to retain them and develop their expertise.

of these and resources. While progress has been made in the period of the staff increase ways of funding
of these resources prevented. It is not clear how to develop further programme built on this

66. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine

Dependence. *Br J Addict*

1987;82:1121-1133.

67. West R, Gilman A, Costa F, Zhou X, Brouard R, Nannamaker J, et al. The ATTEMPT

Cohort: A Multinational Longitudinal Study of Predictors, Patterns, and Consequences of

Cessation of Tobacco Use. *Arch Gen Psychiatry* 2004;61:103-111.

Addiction In Press.

68. Rangar-Moore J, Muramatsu ML, Matthews E. Effectiveness of the nicotine

transdermal system (NDS) for smoking cessation. *Appl Health Behav* 2004;28(4):299-300.

69. Gilman A and psychiatric cases. *Br J Psychiatry* 2001;178:136-7.

70. Paulat CB, Goshvassan G, Russell MW, Samuels R, Gilman A, et al. Higher

nicotine patches increase one-year smoking cessation rates: results from the

European ACE Trial. Collaborative European Anti-Smoking Evaluation. European

Respiratory Society [europeansoc]. *Eur Respir J* 1999;13(2):243-46.

71. Niazanck R, Shand W, Alkaram D, Gohlsch M, Lyons MC, et al. Smoking

cessation with nicotine replacement therapy: for the treatment of tobacco dependence a

randomized trial. *Ann Intern Med* 2004;140(6):426-33.

72. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

73. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

74. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

75. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

76. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

77. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

78. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

79. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

80. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

81. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

82. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

83. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

84. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

85. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

86. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

87. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

88. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

89. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

90. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

91. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

92. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

93. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

94. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

95. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

96. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

97. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

98. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

99. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

100. Lichtenstein S, Fischhoff I, Phillips L. *Statistical Foundations of Risk Analysis*. John Wiley & Sons, New York, 1980.

85. Fong GT, Cummings KM, Shopland DR. Building the evidence base for effective tobacco

Tob Control 2006;15 Suppl 3:iii1-2.

effective smoking cessation interventions for the health care system - eLearning
Authority Thorax 1998;53 Suppl 5 Pt 1:S1-19.

smoking cessation services: service and monitoring guidance.
London: 2001.

87. Department of Health. NHS Smoking
2001/02. Issued 11 April 2001.

pharmacokinetics of single and repeated doses of
nicotine replacement product. Nicotine & Tobacco Research

88. D'Orlando KJ, Fox BS. Tolerability of
nicotine with The Straw, a novel
2004;6(1):63-70.

er AR, Gitchell JG, Henningfield JE. Nicotine delivery systems
2005;2(3):563-77.

89. Shiffman S, Fant RV, Rughbalt
Expert Opin Drug Deliv 200

Effects of cigarette smoking and carbon monoxide on nicotine
Clin Pharmacol Ther 2000;67(6):653-9.

90. Benowitz NL, Jacob P, 3rd.
and cotinine metabolism. C

tion of the mood and physical symptoms scale (MPSS) to assess
pharmacology (Berl) 2004

91. West R, Hajek P. Evaluation
cigarette withdrawal. Psych

bert D. Recommendation for the assessment of tobacco craving and

92. Shiffman S, West R, Gill

control drug use: the addicts
10

94. McInnes J, McKernan N. Identify and Recovery from Dependence
perspective. Drugs, Education, Intervention & Policy 2001; 6:47

of efficacy on smoking lapses and relapses. Health Psychol 2006; 25(1): 215-24

one versus retrospective recall of smoking lapses. J Consult Clin Psychol

comparison of real-time
1007-6571/07/202 200

98. Shiffman S, Gwaltney K, Ahluwalia D, et al. Smoking cessation: the
smoking relapse. Health Psychol 1986;5 Suppl:13-27.

99. Kassel JD, Stroud LR, Paronis CA. Smoking, stress, and negative affect: correlation

